Affinia Therapeutics Presents Preclinical Data from Novel Cardiotropic and BBB-Permeable AAV Capsids Program for Inherited Cardiomyopathy and Sporadic ALS at the American Society for Gene and Cell Therapy 2024 Annual Meeting
Novel cardiac capsid transduces more than 90% of cardiomyocytes in non-human primates (NHP) and off-targets the liver and dorsal root ganglia (DRG); shows safety and efficacy in mouse model of …
